Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer

Acta Oncologica

Volumn 57, Issue 8, 2018, Pages 1127-1128

  Jensen, Kristian Hastoft ^a   Persson, Gitte ^a   Bondgaard, Anna Louise ^a   Pøhl, Mette ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; NIVOLUMAB; PEMETREXED; TUBERCULOSTATIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACID FAST BACTERIUM; ADULT; ADVANCED CANCER; BODY WEIGHT LOSS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COUGHING; DRUG WITHDRAWAL; FEVER; FINE NEEDLE ASPIRATION BIOPSY; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LUNG ADENOCARCINOMA; LUNG INFILTRATE; LUNG LOBECTOMY; LUNG TUBERCULOSIS; LYMPH NODE BIOPSY; MALE; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM TUBERCULOSIS COMPLEX; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; VIDEO ASSISTED THORACOSCOPIC SURGERY; WILD TYPE; CHEMICALLY INDUCED; DISEASE PREDISPOSITION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY; TREATMENT WITHDRAWAL;

ANTITUBERCULAR AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNOCOMPROMISED HOST; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIVOLUMAB; PROGRAMMED CELL DEATH 1 RECEPTOR; TUBERCULOSIS, PULMONARY; WITHHOLDING TREATMENT;

EID: 85041368920     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/0284186X.2018.1433877     Document Type: Letter

References (5)

1. Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124:271–277.
2. Lee J, Chan A, Tang T., Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma. Acta Oncol. 2016;55:519–520.
3. Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11:2238–2240.
4. Tousif S, Signh Y, Prasad DVR, et al. T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS ONE. 2011;6:e19864.
5. Barber DL, Mayer-Barber KD, Feng CG, et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol. 2011;186:1598–1607.